triple GIP/GLP-1/glucagon agonistGLP-1 AgonistsVerified Match
Retatrutide
A first-in-class triple GIP/GLP-1/glucagon receptor agonist from Eli Lilly. Phase 3 trials show up to 28.7% weight loss (TRIUMPH-4). Represents the next frontier in incretin-based obesity treatment.
weight-lossblood-sugar-controltriple-agonistexperimental
Best vendor: NxGen Bio Med
3D Structure
3D Structure
4831.44 Da
Lab Tested
Yes
Harmful Ingredients
0
Contaminants
None
Tested Purity
100.0%
Batch Consistency
P20250108RT3001
Mass Spec Profile
ESI-MS (computed)
Batch Info
Latest Batch—
Total Tests172
Unique Vendors170
Vendor Comparison
| Vendor | Status |
|---|---|
N Next Day Peptides | Pending |
N Next Day Peptides | Pending |
N Next Day Peptides | Pending |
H Henan Sahe Peptide | Verified |
Y Yimei | Verified |
Analysis Summary
Purity Standard
Passes (≥98%) — 100.0%
Lab Reports
172 reports on file
Summary
A first-in-class triple GIP/GLP-1/glucagon receptor agonist from Eli Lilly. Phase 3 trials show up to 28.7% weight loss (TRIUMPH-4). Represents the next frontier in incretin-based obesity treatment.